Mycophenolate mofetil
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Scleroderma, Systemic
Conditions
Scleroderma, Systemic
Trial Timeline
May 1, 2006 → Jan 1, 2009
NCT ID
NCT00333437About Mycophenolate mofetil
Mycophenolate mofetil is a pre-clinical stage product being developed by Roche for Scleroderma, Systemic. The current trial status is completed. This product is registered under clinical trial identifier NCT00333437. Target conditions include Scleroderma, Systemic.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01213394 | Phase 3 | Terminated |
| NCT01014442 | Phase 3 | Completed |
| NCT00333437 | Pre-clinical | Completed |
| NCT00187941 | Phase 1 | Completed |
| NCT00788567 | Phase 3 | Completed |
| NCT00166244 | Approved | Completed |
| NCT00199667 | Approved | UNKNOWN |
| NCT00193635 | Phase 1 | Completed |
Competing Products
15 competing products in Scleroderma, Systemic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IVA337 + Placebo | Inventiva | Phase 2 | 47 |
| Cuprimine (penicillamine) | Merck | Pre-clinical | 23 |
| rapcabtagene autoleucel + rituximab | Novartis | Phase 2 | 52 |
| STI571 | Novartis | Phase 2 | 52 |
| Imatinib mesylate | Novartis | Phase 2 | 52 |
| imatinib mesylate | Novartis | Phase 2 | 52 |
| Mycophenolate mofetil + Cyclophosphamide + Placebo | Roche | Phase 2 | 52 |
| Fludarabine + Cyclophosphamide + Thymoglobulin | Amgen | Phase 1 | 32 |
| BMS-986020 | Bristol Myers Squibb | Phase 2 | 51 |
| dasatinib | Bristol Myers Squibb | Phase 1/2 | 40 |
| Abatacept + Placebo | Bristol Myers Squibb | Phase 1/2 | 40 |
| AVID200 | Bristol Myers Squibb | Phase 1 | 32 |
| Rilonacept | Regeneron Pharmaceuticals | Phase 1/2 | 40 |
| Riociguat + Placebo | Bayer | Phase 2 | 49 |
| Riociguat (Adempas, BAY63-2521) + Placebo | Bayer | Phase 2 | 49 |